Literature DB >> 18040694

Long-term outcome of home dipstick testing for hematuria.

Ralph Madeb1, Edward M Messing.   

Abstract

The most common symptom of bladder cancer (BC) is hematuria and microhematuria will occur in virtually all patients with BC if one tests for it frequently enough. However, hematuria even when caused by serious disease, often is intermittent, and once above some threshold the degree of microhematuria is unrelated to the seriousness of its underlying cause. Based on these principles a BC screening study was conducted to determine if repetitive hematuria testing can detect BC early and whether this resulted in reduced BC mortality, in long-term follow-up compared with disease related outcomes of a contemporary unscreened population similar to the one taking part in screening. The study and the long-term outcomes are reviewed. At 14 years minimum follow-up, none of the 21 men diagnosed with BC by hematuria screening have died of the disease; 12 were still alive and 9 had died of diseases other than BC, with a median survival of 8.8 years. The lower overall mortality in screenees with BC was primarily because of the reduced mortality from BC in that group. Screening had effected a shift of the high grade tumors to earlier (more superficial) stages at diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040694     DOI: 10.1007/s00345-007-0224-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  22 in total

1.  Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Authors:  Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

2.  Detection of bladder cancer using a point-of-care proteomic assay.

Authors:  H Barton Grossman; Edward Messing; Mark Soloway; Kevin Tomera; Giora Katz; Yitzhak Berger; Yu Shen
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

3.  Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

Authors:  H Barton Grossman; Mark Soloway; Edward Messing; Giora Katz; Barry Stein; Vahan Kassabian; Yu Shen
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

4.  Long-term outcome of hematuria home screening for bladder cancer in men.

Authors:  Edward M Messing; Ralph Madeb; Terry Young; Kennedy W Gilchrist; Lora Bram; E Barry Greenberg; John D Wegenke; Laura Stephenson; Jason Gee; Changyong Feng
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

Review 5.  Current bladder tumor tests: does their projected utility fulfill clinical necessity?

Authors:  V B Lokeshwar; M S Soloway
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

Review 6.  Urinary bladder tumor markers.

Authors:  Vinata B Lokeshwar; Marie G Selzer
Journal:  Urol Oncol       Date:  2006 Nov-Dec       Impact factor: 3.498

Review 7.  Gender, racial and age differences in bladder cancer incidence and mortality.

Authors:  Ralph Madeb; Edward M Messing
Journal:  Urol Oncol       Date:  2004 Mar-Apr       Impact factor: 3.498

Review 8.  Markers of detection.

Authors:  Edward Messing
Journal:  Urol Oncol       Date:  2007 Jul-Aug       Impact factor: 3.498

9.  Hematuria home screening: repeat testing results.

Authors:  E M Messing; T B Young; V B Hunt; M A Newton; L L Bram; A Vaillancourt; W J Hisgen; E B Greenberg; M E Kuglitsch; J D Wegenke
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

10.  The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks.

Authors:  E M Messing; T B Young; V B Hunt; S E Emoto; J M Wehbie
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

View more
  8 in total

Review 1.  Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.

Authors:  V Urquidi; C J Rosser; S Goodison
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.

Authors:  Na Yang; Shun Feng; Kerby Shedden; Xiaolei Xie; Yashu Liu; Charles J Rosser; David M Lubman; Steven Goodison
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

3.  Patients with microscopic and gross hematuria: practice and referral patterns among primary care physicians in a universal health care system.

Authors:  Faysal A Yafi; Armen G Aprikian; Simon Tanguay; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

4.  Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Authors:  Ralph Madeb; Dragan Golijanin; Katia Noyes; Susan Fisher; Judith J Stephenson; Stacey R Long; Joy Knopf; Gary H Lyman; Edward M Messing
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

Review 5.  Molecular screening for bladder cancer: progress and potential.

Authors:  Anirban P Mitra; Richard J Cote
Journal:  Nat Rev Urol       Date:  2010-01       Impact factor: 14.432

6.  Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria.

Authors:  Deep Trivedi; Edward M Messing
Journal:  BMC Urol       Date:  2009-09-10       Impact factor: 2.264

7.  Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People.

Authors:  Mohammed Shahait; Muhammad Bulbul
Journal:  Bladder Cancer       Date:  2016-10-27

8.  Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific.

Authors:  Brian Duggan; Declan O'Rourke; Neil Anderson; Cherith N Reid; Joanne Watt; Hugh O'Kane; Ruth Boyd; David Curry; Mark Evans; Michael Stevenson; Mary Jo Kurth; John V Lamont; Peter Fitzgerald; Mark W Ruddock
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.